Insulin production was studied in transgenic mice expressing the human insulin gene under the control of its own promoter. Glucose homeostasis during a 48-h fast was similar in control and transgenic mice, with comparable levels of serum immunoreactive insulin. Northern blot and primer extension analyses indicated that more than twice as much insulin mRNA is present in pancreata from transgenic mice. Primer extension analysis using oligonucleotides specific for mouse insulins I and II or for human insulin, showed that the excess insulin mRNA was due solely to expression of the foreign, human insulin gene. The ratio of mRNA for mouse insulin I and II was unaffected by coexpression of human insulin. There were coordinate changes in the levels of all three mRNA during the 48-h fast, or after a 24-h fast followed by 24-h refeed. Despite the supraphysiologic levels of insulin mRNA in the transgenic mice, their pancreatic content of immunoreactive insulin was not significantly different from controls. The comparison of the relative levels of human and mouse insulin mRNAs with their peptide counterparts (separated by HPLC) indicates that the efficiency of insulin production from mouse insulin mRNA is greater than that from human, stressing the importance of posttranscriptional regulatory events in the overall maintenance of pancreatic insulin content. (J. Clin. Invest. 1993. 92:272-280.)
insulin output from the pancreas results in the maintenance of a physiologic "set point" for insulin production. This set point is reflected in the pancreatic insulin content and circulating insulin levels encountered in given mammalian species and will be altered in response to a change in diet or physical activity, and in certain disease states including, most notably, diabetes.
Relatively little is known concerning the mechanism by which this set point for insulin production is established. Mice present a useful model for understanding the regulation of insulin production since, like rats ( 10-16), they possess two nonallelic insulin genes (insulin I and II) (17) (18) (19) . In order to study further the relative contribution of transcriptional and posttranscriptional events in the establishment of the insulin set point, we have now examined this process in transgenic mice in which the human insulin gene is expressed in pancreatic B cells under the control of its own promoter (20) . These mice are known to express significant levels of human insulin in a tissue-specific and regulated fashion (20) . We have measured the relative levels of human and mouse insulin mRNAs and peptides in transgenic mice and compared them with those for mouse controls. The total insulin mRNA was more than twofold higher in the transgenic mice. Approximately one half of this insulin mRNA was derived from transcription of the human gene, yet, strikingly, total (mouse plus human) serum insulin and pancreatic insulin content were similar in transgenic and control animals. HPLC analysis ofpancreatic insulin revealed the expected ratio of mouse insulin I:I in control mice, with no change in this ratio in transgenic animals. Human insulin accounted for some 28% of total insulin in the pancreas ofthe transgenic mice. Taken together, these findings strongly suggest that the establishment of a physiological set point for insulin production is dominated by posttranscriptional regulatory events.
Methods
Breeding and care of mice. Transgenic mice expressing the human insulin gene under the control of its own promoter were generated as described in detail by us previously (20) . Mice were maintained ad libitum (unless stated otherwise for fasting and refeeding) on Prolab Rat, Mouse and Hamster 3000 (Agway, Waverly, NY). Positive male transgenic mice were mated with control females. To identify mice carrying the human insulin gene, small tail segments were taken, and total genomic DNA was purified and screened by Southern blot hybridization on nitrocellulose using standard procedures (20) .
Serum insulin and glucose. Mice were bled periorbitally after ether anesthetization under the appropriate physiological regimen. Glucose assays were performed as recommended by the manufacturer of the assay kit (Sigma Immunochemicals, St. Louis, MO). Insulin was measured using a '25I-insulin double-antibody radioimmunoassay kit according the manufacturer's instructions (Diagnostic Products Corp. Preparation ofRNA. After the mice had been bled, they were killed by cervical dislocation. Pancreata were dissected and the tissue snap frozen in liquid nitrogen. Total cellular RNA was extracted and purified from the tissue samples, using the guanidinium isothiocyanite procedure as described (21 ) . The purity ofthe RNA was assessed by determining the A260,280 ratio (> 1.8) and by visualizing the ribosomal RNA after agarose gel electrophoresis with ethidium bromide.
Northern blot hybridization. Total insulin RNA was quantified using Northern blot hybridization as described (22) . RNA samples (10 , 0.1% SDS, 1 mg/ ml denatured salmon sperm DNA, 50 mM NaPO4, pH 6.5). The following day, the solution was replaced with hybridization buffer (prehybridization buffer containing 10% dextran sulfate) and 5 x 105 cpm/ ml of the radioactive probe. The probe was generated by random-primer synthesis (Boehringer Mannheim) of a 1.1 kb Aval fragment containing the human genomic insulin gene purified from plasmid pHINT 5 as previously described (20) . Hybridization was carried out for at least 16 h at 42°C. The filters were washed (twice with lX SSC, 0.1% SDS at room temperature for 15 min; once each with 0. IX SSC, 0.1% SDS at 37°C for 15 min; 0.1X SSC, 0.1% SDS at 55°C for 30 min), dried, and the total amount of insulin mRNA from each of the samples was directly quantified using a -ray emission counter (Betascope 603; Betagen Inc., Framingham, MA).
Primer extension assaysfor quantification ofinsulin-specific RNA.
Primer extension assays were used to quantify each of the insulin mRNAs as described (24) (25) (26) . Each oligonucleotide (oligo) is listed in Table I and the corresponding region of the insulin gene depicted in Fig. 1 . The oligos were synthesized on an Applied Systems (Mentor, OH) machine using phosporamidite chemistry and gel purified. After we determined the concentration, each oligo was optimized to yield saturation by T4 polynucleotide kinase and for primer extension reactions. Each oligo was tested for its specificity, using standard sequencing reactions. When the oligos were used in combination, there was no detectable interference or reduction of the primer-extended products.
Briefly, 10 Mg of total cellular RNA was resuspended in 5 ,ul of reverse transcriptase buffer (50 mM Tris-HCI, 60 mM NaCl, 10 mM dithiothreitol, pH 8.5) and hybridized with 1 pmol of primer that had been 5'-end labeled by treatment with polynucleotide kinase and y_[32pJ_ ATP at a specific radioactivity of -5MgCi/pmol. The primer was extended using the AMV reverse transcriptase (2 U, Bio-Rad Laboratories), and the samples were subsequently electrophoresed on 6.0% acrylamide, 7.0 M urea sequencing gels. The gels were transferred to 3MM filter paper (Whatman, Inc., Clifton, NJ), dried, and the samples finally quantified directly using the Betascope 603 counter.
Biochemistry
Acid ethanol extraction ofpancreas. Extraction was performed according to the method of Curry (27) with slight modifications. Pieces of pancreas (stored at -70°C) were weighed (-0.2-0.4 g wet wt), suspended in 4 ml acid ethanol ( 1:3 vol/vol of 0.7 M HCl/ethanol) containing 0.1% BSA and, after being cut into small fragments, homogenized on ice, with 4 x 10-s bursts with 1 min interval between each burst, using a Polytron Tissue Grinder (Kinematica, Lucerne, Switzerland). The blades of the grinder were rinsed with 1 ml acid ethanol/ BSA and the pooled suspension incubated at 4°C overnight with gentle mixing. The homogenates were then centrifuged (3,000 g, 20 min, 4°C) and the supernatants set aside on ice. The pellets were resuspended in 4 ml acid ethanol/BSA and treated as above, but with only a 2-h incubation period at 4°C. This was repeated once. The three supernatants (total volume 15 ml) were pooled and centrifuged at 21,700 g for 25 min at 4°C to pellet all debris. The supernatant was split into 3 x 5 ml and transferred to a Speedvac Concentrator (Savant Instruments, Farmingdale, NY) and ethanol evaporated by connection to a water pump for 5 h.
After evaporation of ethanol, the volume of the extracts was adjusted to 7 ml with water, and the pH raised to 9.0 with 10 M NaOH. Half of each extract was then loaded onto C18 Sep-Pak cartridges (Waters Associates, Milford, MA) preactivated with 5 ml acetonitrile Figure 1 . Line diagram of insulin genes with oligonuci ization sites. The three insulin genes are shown proporti regions represent introns, the hatched regions represen quences, and the white regions represent untranslated specific oligonucleotides utilized for primer extension a sequences see Table I ) are shown beneath each gene. a indicates the region of specificity on the mRNA transci and 5 ml H20. Salts were removed by passing 5 ml 0.1% acid (TFA) through the cartridges, small hydrophilic I with 5 ml 20% acetonitrile in 0.1% TFA and insulin fina 3 ml 45% acetonitrile in 0.1% TFA into a tube containi BSA. After evaporating acetonitrile (Speedvac connec pump) the samples were frozen and then lyophilized. T uct was redissolved in 250 Ml 0.1% TFA and centrifuged 10 min to remove any particulate material that would interferred with the subsequent analysis by HPLC. The were kept at -70'C pending analysis. To attempt to quantify the extraction and Sep-Pak pi cedures, and in particular to ensure that there was no s just one of the three insulin species under study, the fol experiments were performed. To control for the efficienc of insulin from the pancreas, an aliquot of human 1211 with 3H-rat insulin I + 11 (prepared by biosynthetic label followed by HPLC purification of the labeled insulin) w, acid ethanol before grinding the tissue. Recovery of all tive insulin species was > 90%, with no detectable deg sessed by HPLC. It must be stressed, however, that this control experiment, since the exogenous, labeled, insu added to the inside of the cells to be extracted. It can sumed that extraction ofinsulin from cells per se is essen tive, with any potential losses due to degradation or ads sequent steps. The results are thus comforting in that the any selective loss ofjust one of the three labeled insulin Quantification of yield from the Sep-Pak purifici achieved by loading pancreas extracts containing knov immunoreactive insulin, and monitoring the recovery say. For control mice, the yield was 86.8±6.6% (n = 27' genic mice 10±1+3% (n = 20). On occasion, there was a low yield (-20%) from a single Sep-Pak cartridge, known intralot variability ofthese cartridges. Even whet there was no selective loss ofjust one insulin species, sij aliquot of the same extract was passed over a new Sep and the HPLC profiles of immunoreactivity then compa preparations, there was no change in the relative amoui insulins.
Radioimmunoassay. Insulin was measured by radioimmunoassay -I 1 using the charcoal-dextran separation method (28 [lowing control
Louis, MO). The comparison of the amount of insulin eluting from :y ofextraction HPLC with that injected confirmed our previous observations ofquan--insulin mixed titative recovery using similar HPLC systems ( 16, 19, 29, 30 Relative amounts ofmouse insulins I and II and ofhuman insulin in thepancreas ofcontrol and transgenic mice. Previous characterization of the transgenic mice indicated that human insulin mRNA was present in islets and that human C-peptide (presumably derived from correctly processed human proinsulin) was secreted into the circulation (20) . Having established that serum insulin levels in the transgenic mice (derived from the mouse I, mouse II, and human insulin genes) were almost identical to those in controls (derived from the two mouse insulin genes alone), it would have been interesting to be able to establish the contribution of each individual insulin peptide to the total insulin immunoreactivity measured in the serum. This would, however, have demanded accumulating serum from a prohibitive number ofmice in order to have measurable amounts of insulin eluting in fractions from HPLC. We therefore elected to determine the relative contribution of human, mouse I, and mouse II insulin to pancreatic insulin content in the two groups of mice.
Pancreas extracts were prepurified and concentrated by passage through Sep-Pak cartridges before injection onto the HPLC system. Each fraction eluting from HPLC was subjected to radioimmunoassay using rat insulin standard for fractions eluting with mouse insulins, and human insulin standard for those eluting with human insulin. Note that rat and mouse insulins I and II have identical sequences and that insulins I and II display identical cross-reactivity in the radioimmunoassay. Representative elution profiles are shown in Fig. 3 . Only two immunoreactive peaks were seen for control pancreas (top), eluting as mouse insulins I and II, with a third, minor peak eluting earlier than the two insulins. This material has been identified as mouse insulin II oxidized at methionine B29 (29) , and for the purposes of calculating the relative amounts of the various insulin species is considered as mouse insulin II. As expected for the pancreas of a mouse ( 15, 19) , there was more than twice as much insulin II than I.
The elution profile for an extract of transgenic mouse pancreas differed by the striking appearance of material coeluting with human insulin (Fig. 3, bottom) Fig. 3 is thus truly representative.
In transgenic animals fed ad libitum, human insulin accounted for 28.2% of pancreatic insulin stores. There was no change in the ratio of mouse insulin 1:II due to the expression ofthe human insulin gene (Table II) Insulin was extracted in acid ethanol. Total IRI for controls was measured using a rat insulin standard (rat and mouse insulin being identical in sequence) whereas for transgenic mice the standard was composed of 25% human/75% rat insulin (since human and rat insulin do not cross-react in a parallel manner in the radioimmunoassay). The percentage ofthe individual insulin species was based on HPLC analysis (see legend to Fig.  3) . The results are presented as the mean±SEM.
The total immunoreactive insulin measured in pancreas extracts of control and transgenic mice was not found to be markedly changed during the fasting period (Table II) . There was, however, considerable interanimal variability that might have masked any minor changes in pancreatic insulin content upon fasting. Of greater significance was the finding that the immunoreactive insulin content of the pancreas of transgenic mice was not significantly different from that of the controls. For measuring the immunoreactive insulin content ofthe control mice pancreas, a standard consisting of a mixture of rat insulin I and II was used. Cross-reactivity in the radioimmunoassay for human insulin is, however, higher than for mouse (rat) insulin. For measuring insulin in the pancreas of transgenic mice, it was therefore necessary to use a standard consisting of 75% rat insulins mixed with 25% human insulin (this being close to the mean percentage of human insulin in the pancreas of transgenic mice, as shown above).
Quantification oftotal insulin mRNA by Northern blot analysis. The data showing similar levels of insulin in the circulation and in the pancreas of control and transgenic mice under all conditions studied suggested that similar levels of insulin mRNA would also be found in the pancreas of the two groups of mice. Surprisingly, such was not the case. When RNA purified from pancreas was quantified using Northern blot analysis, there was approximately two to three times more total insulin mRNA (mouse plus human) in the transgenic than in the control mice (Fig. 4) .
Primer extension analysis Total insulin mRNA. Since the apparent elevation of insulin mRNA in the transgenic mice pancreas seen by Northern hybridization analysis may have been artifactual due to an enhanced specificity of the probe for human rather than mouse insulin mRNA, primer extension analysis was performed to confirm and extend this finding. After comparison to the entire GenBank library to assure minimal homology to extrinsic nucleic acid sequences, INS, an oligonucleotide specific for all three insulin mRNAs, was generated ( Fig. 1 and Table I ). The oligonucleotide was 5' radiolabeled, incubated with total pancreatic cellular RNA, and primer extended using reverse transcriptase. The primer extension products were separated on denaturing urea polyacrylamide gels and quantified directly with a 13-ray emission counter.
Using the INS oligonucleotide for primer extension analysis of pancreatic RNA confirmed the results obtained by Northern blot hybridization, showing an -2.2-fold increase in total insulin mRNA in the transgenic mice ( Fig. 5 ; Table  III) . Control experiments using RNA extracted from tissue other than pancreas revealed no detectable insulin mRNA signal.
As expected from previous studies in the rat (31 ), there was a progressive decrease in insulin mRNA levels during the 48-h fast, with a pronounced rebound during the 24-h refeeding period following a 24-h fast (Table III) . 1 2 3 4 5 6 7 8 9 10 11 12 0.6 kb_ Figure 4 . Northern hybridization analysis. Control and transgenic mice were sacrificed after feeding ad libitum. The samples were subjected to electrophoresis on 1% agarose-formaldehyde gel, transferred to a nylon membrane, and hybridized against a random-primer synthesized probe derived from human insulin cDNA. Control mice (lanes 1-6); transgenic mice (lanes 7-12). 10 . Primer extension analysis of human and mouse insulin mRNA. The specificity of the INS, MINS 3, and HINS oligonucleotide probes (see Fig. 1 and Table I ) in detecting specific insulin mRNAs was initially evaluated using total pancreatic RNA derived from control and transgenic mice fed ad libitum. Total mouse (I + II) insulin mRNA. The increase in insulin mRNA in the pancreas oftransgenic mice could have been due to the additional presence of human insulin mRNA and/or to changes in the levels of one or both of the endogenous mouse insulin mRNAs. To determine the relative amounts of total mouse insulin mRNA in the two groups of mice, MINS 3, an oligonucleotide specific for both mouse I and II insulin mRNA but significantly divergent from human, was prepared (Fig. 1,  Table I ). Primer extension analysis using this oligonucleotide revealed that there was no significant difference in the level of total mouse insulin mRNA in the pancreas ofcontrol or transgenic mice (Fig. 5 , Table III ). Under all conditions tested, total mouse insulin mRNA content in transgenic animals was within 20% ofthat ofcontrols. This strongly suggested that the excess insulin mRNA in the transgenic pancreata was due to the presence of human insulin mRNA.
Human insulin mRNA. Primer extension analyses were also performed using HINS, an oligonucleotide specific for a sequence unique to human insulin mRNA (Fig. 1, Table I ). The results (Fig. 5, Table III ) confirm that the magnitude of both the decrease of human insulin mRNA during fasting of transgenic mice, as well as the increase upon refeeding, were similar to those observed for the mouse insulin mRNAs. No human insulin mRNA was detected by primer extension assay using total cellular RNA derived from control mouse pancreas, confirming the specificity of the HINS oligonucleotide.
Mouse I vs. II insulin mRNA. Previous reports concerning the ratio of mouse insulin 1:11 mRNA have been inconsistent with one another (17) (18) (19) , possibly reflecting physiologic variability. To determine whether the coexpression of the human insulin gene in transgenic mouse B cells affected this ratio, two oligonucleotides were designed, each specific for a region unique to either mouse insulin I (MINS 1) or II (MINS 2) mRNA (Fig. 1, Table I ). It was found that these oligonucleotides could be used for primer extension analysis either individually or in combination (Fig. 6) , showing that the primers are specific and noninterfering. The data show that mouse insulin I mRNA is approximately twice as abundant (2.1±0.1, n = 6) as insulin II mRNA. This value, however, may be influenced by the specific activity of the two radiolabeled oligonucleotide primers, and it is therefore not intended that this ratio be considered in quantitative terms. The ratio can, nonetheless, be used with confidence for comparative purposes, and it was found to be similar for control and transgenic mice, strongly suggesting that expression ofhuman insulin does not affect the relative expression of the two mouse insulin genes.
Discussion
Expression of the human insulin gene under the control of its own promoter in transgenic mice has been described by other groups (32) (33) (34) (35) (36) as well as our own (20) . These earlier studies showed that expression of the human gene was limited to the pancreatic B cells of such mice (20, (32) (33) (34) (35) (36) , although more recently, it has been found that low levels of human insulin mRNA can also be detected in other tissues, including the brain, in one particular line oftransgenic mice (S. J. Chan and D. Steiner, personal communication). Both the synthesis and the release ofhuman insulin were regulated by glucose in much the same manner as the two endogenous mouse insulins. The expression ofthe foreign human insulin gene is presumed to be dependent upon the presence of a defined upstream region known to carry the cis-elements responsible for tissue-specific transcription (36) . No attempt was made in these earlier studies, however, to compare the relative amounts ofthe three insulin mRNAs (mouse I, mouse II, and human) with those ofthe corresponding peptides. This comparative study has now revealed that the regulation of steady-state pancreatic insulin content is rather more complex than was previously supposed, with posttranscriptional events playing a crucial role. Taken together, the data obtained from the ar lin mRNA show that in the pancreata oftransge was -2.2-fold more insulin mRNA than in thc and that the increase was due to the addition; human insulin mRNA. Neither the total amour + II) insulin mRNA nor the relative amounts o vidual mouse insulin mRNAs were affected by the expression ofthe human gene. During the fasting and refeeding there were parallel changes in mouse and human mRNA, thereby confirming the coordinate physiological regulation of the endogenous and exogenous insulin genes. In the present study, the steady-state levels of pancreatic insulin mRNA and peptides have been compared. As discussed in greater detail below, such data do not allow for quantification of rates of production or degradation of either mRNA or peptides. Despite this reservation it is apparent that the interplay between physiologic mediators and the various steps in insulin synthesis results in the maintenance ofa physiologic set point for insulin content; that such a set point exists is illustrated by its maintenance in the face of supraphysiologic levels ofinsulin mRNA. Thus, despite the doubling of total insulin mRNA in the pancreas of transgenic mice, the pancreatic content of immunoreactive insulin was not significantly different from that of the control group regardless of the feeding regimen, and neither was glucose homeostasis affected.
It is presumed that the set point is initiated in utero and can be changed; witness the alteration in insulin production that When the relative amounts of the insulin mRNAs in our transgenic mice are compared with those of the corresponding peptides, insulin production from mouse insulin mRNA is clearly more efficient than that from human. The interpretation of the data is somewhat complicated by the fact that we have simply measured steady state levels of both insulin mRNA and peptide rather than their rates of synthesis and disappearance. It is thus possible that human insulin is in fact produced more efficiently than we imagine, but that its rate of disappearance from the pancreatic B cells is more rapid than either ofthe two mouse insulins, leading to a lower steady state pancreatic content of the human peptide. Insulin disappearance from the pancreas is the sum ofsecretion and intracellular degradation (2, 37) . Based upon current knowledge of human insulin production in transgenic mice, it appears likely that all three insulins are synthesized in the same B cells and, one must presume, packaged together in the same granules (36) . Ifthat is indeed the case, it is difficult to imagine that human insulin could be secreted in preference to the mouse insulins, the unit of secretion being a granule regardless of its content (2, 38) . The degradation of insulin in the B cell arises by crinophagy (fusion ofgranules with lysosomes) (2, 39) . Thus insulin degradation, like secretion, depends upon the granule as the basic operational unit rather than its contents.
Clearly, some posttranscriptional event must be relatively less efficient for human insulin than for mouse insulin. Since HPLC analysis revealed no accumulation of human proinsulin in the transgenic mouse pancreas (data not shown), it must be assumed that slow conversion of human proinsulin is not the explanation for the relatively low levels of human insulin peptide and that an event prior to formation ofproinsulin itself, or the stability of newly formed proinsulin, must be responsible. When one considers the cascade of posttranscriptional events implicated in insulin production (1, 2) , this limits the steps that may be rate limiting in the production ofhuman insulin to translation itself, translocation ofpreproinsulin to the lumen of the rough endoplasmic reticulum, conversion of preproinsulin to proinsulin, and possibly the stability of newly synthesized proinsulin molecules within the rough endoplasmic reticulum or in transit to secretory granules.
From the data presented here, it can be concluded that the abundance ofa given species ofinsulin mRNA cannot be taken as an index of the relative amount of insulin being produced and stored in the pancreas. This stresses the fundamental importance (and perhaps dominance) of posttranscriptional events in the overall regulation of pancreatic insulin production. It will be essential to understand each of these events, and above all their regulation, in the development of a strategy for insulin gene replacement therapy of diabetes. Such a therapy for diabetes will most likely utilize non-B cells for insulin production (40, 41 ) . In this context, it will be critical to understand not only how the B cell regulates insulin production, but also how to recreate such regulation in an ectopic tissue.
